Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
about
Regulation of glucose homeostasis by GLP-1Dipeptidyl peptidase-4 and kidney fibrosis in diabetesInvestigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?The Concise Guide to PHARMACOLOGY 2013/14: enzymes.Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistanceThe nonglycemic actions of dipeptidyl peptidase-4 inhibitorsPotency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.Saxagliptin for type 2 diabetesDipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.Targeted inactivation of dipeptidyl peptidase 9 enzymatic activity causes mouse neonate lethality.Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity.Diabetes: impaired damage controlIdentification of novel dipeptidyl peptidase 9 substrates by two-dimensional differential in-gel electrophoresis.Differential Expression and Enzymatic Activity of DPPIV/CD26 Affects Migration Ability of Cervical Carcinoma Cells.Inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiationSaxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.An inhibitory antibody against dipeptidyl peptidase IV improves glucose tolerance in vivoPleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: a multicenter, randomized trial.Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver.The serine protease, dipeptidyl peptidase IV as a myokine: dietary protein and exercise mimetics as a stimulus for transcription and releaseIncretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus.The in vivo expression of dipeptidyl peptidases 8 and 9.The dipeptidyl peptidase IV family in cancer and cell biology.Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.Recent patents of dipeptidyl peptidase IV inhibitors.Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.A review of gliptins in 2011.Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.Cardiovascular effects of gliptins.The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].DPP-4 inhibitors: pharmacological differences and their clinical implications.Pharmacokinetic study of saxagliptin in healthy Chinese subjects.Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins.
P2860
Q24563430-BCCDD27A-FE1B-43FA-92CC-07ADB97B4105Q26766089-47618899-4BF4-447D-B14F-F69D4E14C071Q30426407-796DE737-70C8-4035-AB09-2E948081D768Q30486745-FD855CF2-BBB3-4F04-A1AC-BCE426896AEDQ34004470-AE6C2CD7-04D9-4EA4-A046-84ED9EEB1F6AQ34029715-716D1FA8-FE47-4F69-B514-6864635EFC67Q34219918-007A134A-0E5D-4D6F-8CBF-B25F5AEA78F1Q34239784-91AC8796-31FA-4026-ABDB-E1A8556DA3F3Q34273302-9137C095-C61E-46BC-9BAA-281228D4A385Q34620486-D1509FFF-8958-43F6-BD22-0458958ED410Q35026483-8F014855-E835-4B7E-850D-942843FB6F84Q35040181-1D405CDD-1206-4C12-B04E-CE0C0A7F7419Q35067242-D2852394-B5CA-4ADB-A8D3-CC063FD828B4Q35587364-1BA652E5-81AB-4926-B830-38F0FFA79B76Q35691528-BCDA3459-4391-4C84-933D-EDC543A77306Q35723683-F8A918BB-29AF-469B-B656-1572D56C7938Q35916947-F7CECF49-8F1B-484B-9F6E-BABC1481AB4CQ36139126-E4C9FCB7-C70F-49F2-B140-6033D32FC3C9Q36526318-84B0C08F-3704-46EC-A1A0-F3428EDDA5F2Q36818849-B637E891-33DC-4DAC-8BA4-88EAFCFDA928Q36865097-7242EA7D-A9F3-4C3C-A795-6875B55F859FQ37043350-728F7EC8-989C-4C24-997E-C361BE4D0768Q37193295-0A2F1824-83C0-44CE-8159-4ABAC4CAB028Q37366826-8862DD4D-1FE8-4CB9-B963-AD2F743CCE2DQ37389403-B0B3D6BE-D1AE-4AE4-9875-60BAA5342DB4Q37674999-0D2BA3D1-6F4F-4325-A202-AB0FE8A29C19Q37837059-4A482903-5711-49DB-969C-E4BC3BC7C035Q37878396-C8067CB3-15C7-429B-BA68-6EC045ED32CEQ37948110-8D08E43D-1C27-48B9-84B2-A0B58BB13447Q37963451-7CD65389-9E75-49B3-8B63-E0510981D937Q37965612-CB215930-67B6-4F74-8A43-B41CC0EC1F48Q37973413-134BBB02-342E-4ADF-A251-C13FC904AD51Q37992255-45EF7772-AB71-4881-B77D-FABFFE4BF3CAQ38017726-22BEAA9C-08F5-4851-824A-9D2904CCC304Q38072259-49D3AC09-EB4E-4202-8C09-E9C930113BEAQ38205588-26EE560F-087D-4A3D-81DD-445F4DFB5D5EQ38244576-92490820-9E56-4601-B88F-405CFF257649Q38470357-D6819D01-4882-444D-A872-52CA367B8886Q38486819-4C352FBA-3643-4B82-ADEE-C8B4608A348DQ38670397-3E515F35-D131-46C7-B062-EE514BEDC459
P2860
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
@en
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
@nl
type
label
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
@en
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
@nl
prefLabel
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
@en
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
@nl
P2093
P2860
P356
P1433
P1476
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
@en
P2093
Denise M T Yu
Mark D Gorrell
Mark Kirby
Steven O'Connor
P2860
P356
10.1042/CS20090047
P407
P577
2009-09-28T00:00:00Z